RxDoctor Payments Data

Margaret Doku

Family · Buford, GANPI 1437503679

Payments from drug & device makers

$3,097in general payments, 2019–2025

Across 160 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$840
  • Lilly USA, LLC$431
  • AbbVie$271
  • GSK$161
  • AstraZeneca$142
  • Inspire Medical Systems, Inc.$108
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,097 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$37,642
Medicare patients
156
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$37,250
MounjaroTirzepatide20$31,236
SynthroidLevothyroxine Sodium22$1,712
Gabapentin70$1,596
Diclofenac Sodium24$1,438
Albuterol Sulfate HfaAlbuterol Sulfate42$1,319
Atorvastatin Calcium152$1,271
Memantine Hcl ErMemantine Hcl12$1,168
Bupropion XlBupropion Hcl24$961
Levothyroxine Sodium82$888
Metoprolol Succinate64$765
Pantoprazole Sodium57$742
Carvedilol39$644
Rosuvastatin Calcium69$566
Ezetimibe29$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$37,25032 claims
Lilly USA, LLCMounjaro$431$31,23620 claims
AbbVieSynthroid$271$1,71222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Buford

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →